Drug intelligence / Profile preview

mAb41

Development stage: Preclinical
Lead developer: LeafBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular

Overview

mAb41 is a monoclonal antibody being developed by Mapp Biopharmaceutical and its commercial arm, LeafBio, for the treatment or prophylaxis of Respiratory Syncytial Virus (RSV) infection. Administered via intramuscular (IM) injection, the antibody is designed to neutralize the virus, thereby preventing viral entry into host cells and mitigating the severity of respiratory illness. The asset is currently in the IND-enabling stage of development, positioning it as a potential passive immunization or therapeutic candidate for RSV.

Targets

RSV F site II (RSV F antigenic site II)

Beyond the preview

Go deeper on mAb41.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAb41.

Explore the full profile